Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Evommune, Inc. (NYSE: EVMN) (Evommune or the Company), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced...